SecBot SecBot
Insider Cluster (2 insiders) ·Filed May 19, 2026

KALV

KalVista Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago
Insider cluster: 2 insiders, $58K total
Actionable Insight • Neutral

The cluster is too small to drive a trade. Monitor for larger-volume insider sales or a new catalyst (e.g., regulatory updates on sebetralstat) before taking a directional view. The cross-filing amplifiers note this cluster coincides with late-filing/offering/press context, which could amplify impact if a material event emerges, but as a standalone the dollar value is noise.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$26.81
T+0 close · May 19, 2026 · via day close
Latest settled
−0.07%
T+5 · $26.79
Vs SPY
−1.31%
α at T+5
Next horizon
T+20
due 5mo ago
  1. T+0 · May 20 $26.81entry
  2. T+1 · 6mo ago −0.15%α −0.34% · $26.77
  3. T+5 · 6mo ago −0.07%α −1.31% · $26.79
  4. T+20 · due 5mo ago Pending
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two C-suite insiders, the CEO and CMO of KalVista, made nominal open-market sales totaling $58K (-0.004% of $1.4B market cap) on May 18, 2026, alongside option exercises. The dollar value is immaterial relative to market cap, and the sales follow a derivative exercise pattern consistent with routine tax- or vesting-related liquidation rather than informed selling.

Key Financial Metrics

Direction
selling
Total Value
$30.0K
Insiders
2

Key Facts

  • CEO Palleiko sold 1,129 shares ($30K) on May 18 at $26.76
  • CMO Audhya sold 1,032 shares ($28K) on May 18 at $26.76
  • Both insiders had exercised 2,419 derivative shares at $0 on May 17 (non-cash)
  • Total open-market sales = $58K, or ~0.004% of $1.4B market cap

Financial Impact

$58K total insider sales, trivial relative to $1.4B market cap

insider holdingsdilution

Risk Factors

  • A future material adverse event could make even small insider sales appear opportunistic in hindsight

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KALV-1779221126099

Track record

12 reports on KALV

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +4.15% at T+5 after the Apr 17, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Jun 22, 202621w ago 15-12G Bearish 7/10 No price data
  2. Jun 17, 202621w ago EFFECT Neutral 3/10 Entry $27.00 No price data
  3. Jun 11, 202622w ago 8-K Neutral 5/10 Entry $26.99 No price data
  4. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $27.00 No price data
  5. May 19, 202625w ago Insider Cluster Bearish 5/10 Entry $26.81 to $26.79 ▲ +0.07% +1.31% vs SPY
  6. May 19, 202625w ago Insider Cluster Neutral 2/10 Viewing Entry $26.81 to $26.79 ▼ −0.07% −1.31% vs SPY
  7. Apr 29, 202628w ago 8-K Bullish 8/10 Entry $26.67 to $26.71 ▲ +0.15% −2.96% vs SPY
  8. Apr 17, 202630w ago Insider Cluster Bearish 6/10 Entry $20.48 to $19.63 ▲ +4.15% +4.71% vs SPY
  9. Feb 23, 202638w ago Insider Cluster Bearish 6/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
  10. Feb 23, 202638w ago Insider Cluster Bearish 7/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 19, 2026